Thoratec Corp. issued a voluntary Urgent Medical Device Correction Letter to all hospitals who have patients supported with the HeartMate II LVAS reminding them to monitor the expiration date of the backup battery contained within the HeartMate II "Pocket" System Controller, as specified in the product Instructions for Use. This backup battery has a 36-month expiration date. If allowed to expire, an advisory alarm, indicated by a yellow wrench symbol, is triggered. This alarm occurs at 12:00 a.m. on the first day of the month in which the backup battery expires.
September 16, 2015
Feature | Hypertension
September 16, 2015 — Initial results of a landmark clinical trial found patients randomized to a systolic blood pressure ...
September 16, 2015
Feature | ECG | Dave Fornell
The resting electrocardiogram (ECG) has been used as a basic cardiac diagnostic for a century, and while the premise ...
September 16, 2015Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
A novel radiopharmaceutical probe developed at Massachusetts General Hospital (MGH) has the potential of providing physicians with information that could save the lives of patients with ischemic stroke or pulmonary embolism. Both conditions are caused when important blood vessels are blocked by a clot that has traveled from another part of the body. In a report that will appear in the October issue of the journal Arteriosclerosis, Thrombosis and Vascular Biology and has been published online, the MGH team describes using this new probe to conduct full-body scans in an animal model. Preliminary results also were reported earlier this year at the national meeting of the American Chemical Society.
September 16, 2015
Technology | Antiplatelet and Anticoagulation Therapies
AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved Brilinta (ticagrelor) tablets at a new 60mg dose to be used in patients with a history of heart attack beyond the first year. With this expanded indication, Brilinta is now approved to reduce the rate of cardiovascular death, myocardial infarction (MI) and stroke in patients with acute coronary syndrome (ACS) or a history of MI.
September 15, 2015
News | Patient Engagement
Michigan hospitals participating in the American College of Cardiology’s “See You in 7” program demonstrated important reductions in 30-day readmission rates for Medicare heart failure patients compared to non-participating hospitals.
September 15, 2015Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024News | Heart Valve Technology
coramaze technologies GmbH, a German medical device company, announced the closing of a EUR 4.5 million (US$ 5.15 million) series A financing round for the mitramaze valve repair system. The device is a novel concept for transcatheter mitral valve repair (TMVR) intended for treatment of inoperable patients suffering from severe functional mitral regurgitation (fMR).
September 15, 2015
News
The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first facility in the United States to use the EpiAccess system to access the pericardial cavity of the heart during an epicardial ablation.
September 15, 2015
Technology | Implantable Cardioverter Defibrillator (ICD)
Medtronic received the first U.S. Food and Drug Administration (FDA) approval for an implantable cardioverter defibrillator (ICD) system for use with magnetic resonance imaging (MRI) scans. The Medtronic Evera MRI SureScan ICD System is approved for MRI scans on any part of the body without positioning restrictions, which means that patients who depend on life-saving ICDs also now have access to MRI scans if and when they need them. The newly approved system, which will be commercially available in September 2015, includes the Evera MRI ICD and Sprint Quattro Secure MRI SureScan DF4 leads, which must be used together to be considered MR-conditional.
September 14, 2015Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
Feature | EP Lab
Texas Heart Institute (THI) announced that it has received a prestigious American Heart Association grant alongside Rice University. The three-year, $750,000 grant will allow THI and Rice researchers to study and test soft, flexible fibers made of carbon nanotubes. The fibers’ ability to bridge electrical gaps in tissue is a groundbreaking discovery and offers hope to the millions of people affected by cardiac arrhythmias.
September 14, 2015
News | Heart Valve Technology
Startup cardiovascular device manufacturer Valtech Cardio Ltd. announced it has received CE Marking for its Cardioband mitral reconstruction system (Cardioband), a proprietary, implantable mitral reconstruction device with a transfemoral, transseptal delivery system for mitral valve repair.
September 14, 2015
Technology | Analytics Software
Vital Images Inc. recently introduced the VioSuite Image Management and Vitality Solutions Business Intelligence product families, providing healthcare administrators with a robust set of tools to improve system-wide image access and image data analytics. VioSuite and Vitality Solutions, as well as the company’s flagship products VitreaAdvanced and VitreaView software, were showcased at the 9th annual Health Information and Management Systems Society (HIMSS) Asia Pacific Conference and Exhibition.
September 14, 2015Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023
News | Sudden Cardiac Arrest
September 14, 2015 — Healthcare providers can assess a patient’s risk of sudden cardiac death (SCD) following a ...
September 14, 2015
Technology | Antiplatelet and Anticoagulation Therapies
New Haven Pharmaceuticals Inc. announced U.S. Food and Drug Administration (FDA) approval of Durlaza (aspirin) 24-hour extended-release capsules for the secondary prevention of stroke and acute cardiac events, including myocardial infarction.
September 11, 2015
Zevacor Molecular (Zevacor), manufacturer and distributor of positron emission tomography (PET) and single photon emission computed tomography (SPECT) radiopharmaceuticals, announced the arrival of a 70 MeV Cyclotron at its new production facility in Noblesville, Indiana.
September 11, 2015© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now